Literature DB >> 20818299

Adverse drug reactions: Part I.

James M Wooten1.   

Abstract

Pharmacovigilance is the process of identifying, monitoring, and effectively reducing adverse drug reactions. Adverse drug reactions (ADRs) are an important consideration when assessing a patient's health. The proliferation of new pharmaceuticals means that the incidence of ADRs is increasing. The goal for all health care providers must be to minimize the risk of ADRs as much as possible. Steps to achieve this include understanding the pharmacology for all drugs prescribed and proactively assessing and monitoring those patients at greatest risk for developing an ADR. Groups at greatest risk for developing ADRs include the elderly, children, and pregnant patients, as well as others. Pharmacovigilance must effectively be practiced by all health providers in order to avoid ADRs.

Entities:  

Mesh:

Year:  2010        PMID: 20818299     DOI: 10.1097/SMJ.0b013e3181f0c866

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  9 in total

Review 1.  Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Nathan J Cherrington
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-07-03       Impact factor: 4.481

2.  Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models.

Authors:  Mark J Canet; Rhiannon N Hardwick; April D Lake; Anika L Dzierlenga; John D Clarke; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2014-01-02       Impact factor: 3.922

3.  Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Rhiannon N Hardwick; April D Lake; Anika L Dzierlenga; John D Clarke; Michael J Goedken; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2014-12-08       Impact factor: 3.922

4.  Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease.

Authors:  Rhiannon N Hardwick; Craig D Fisher; Mark J Canet; George L Scheffer; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2011-08-30       Impact factor: 3.922

5.  A qualitative exploration of pharmacovigilance policy implementation in Jordan, Oman, and Kuwait using Matland's ambiguity-conflict model.

Authors:  Hamza Y Garashi; Douglas T Steinke; Ellen I Schafheutle
Journal:  Global Health       Date:  2021-08-30       Impact factor: 4.185

6.  Impact of protocol change on individual factors related to course of adverse reactions to chemotherapy for breast cancer.

Authors:  Daniela Polessa Paula; Vanessa I do Brasil Costa; Rosane V Jorge; Flávio F Nobre
Journal:  Support Care Cancer       Date:  2019-05-06       Impact factor: 3.603

7.  Consumer Narratives in ADR Reporting: An Important Aspect of Public Health? Experiences from Reports to a Swedish Consumer Organization.

Authors:  Andreas Vilhelmsson
Journal:  Front Public Health       Date:  2015-09-01

8.  Reduction in exacerbation of COPD in patients of advanced age using the Japanese Kampo medicine Dai-kenchu-to: a retrospective cohort study.

Authors:  Taisuke Jo; Nobuaki Michihata; Hayato Yamana; Yusuke Sasabuchi; Hiroki Matsui; Hirokazu Urushiyama; Akihisa Mitani; Yasuhiro Yamauchi; Kiyohide Fushimi; Takahide Nagase; Hideo Yasunaga
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-12-27

9.  DNA damage by Withanone as a potential cause of liver toxicity observed for herbal products of Withania somnifera (Ashwagandha).

Authors:  Shazia Siddiqui; Nabeel Ahmed; Mausumi Goswami; Anindita Chakrabarty; Goutam Chowdhury
Journal:  Curr Res Toxicol       Date:  2021-02-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.